Source | Evidence on protein | Close homologs |
---|---|---|
Cuervo et al. | no | yes: 0 |
Hassani et al. | no | yes: 0 |
Forrest at al. (metacyclic) | no | yes: 0 |
Forrest at al. (procyclic) | no | yes: 0 |
Silverman et al. | no | yes: 0 |
Pissara et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Pires et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Silverman et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
Jamdhade et al. | no | yes: 0 |
Source | Evidence on protein | Close homologs |
---|---|---|
DeepLoc | ||
SignalP6 | no | yes: 0, no: 8 |
NetGPI | no | yes: 0, no: 8 |
Related structures:
AlphaFold database: A4HG57
Term | Name | Level | Count |
---|---|---|---|
GO:0003676 | nucleic acid binding | 3 | 9 |
GO:0005488 | binding | 1 | 9 |
GO:0097159 | organic cyclic compound binding | 2 | 9 |
GO:1901363 | heterocyclic compound binding | 2 | 9 |
GO:0003723 | RNA binding | 4 | 1 |
Leishmania | From | To | Domain/Motif | Score |
---|---|---|---|---|
CLV_NRD_NRD_1 | 11 | 13 | PF00675 | 0.493 |
CLV_NRD_NRD_1 | 190 | 192 | PF00675 | 0.590 |
CLV_NRD_NRD_1 | 6 | 8 | PF00675 | 0.556 |
CLV_NRD_NRD_1 | 78 | 80 | PF00675 | 0.496 |
CLV_PCSK_KEX2_1 | 10 | 12 | PF00082 | 0.627 |
CLV_PCSK_KEX2_1 | 189 | 191 | PF00082 | 0.589 |
CLV_PCSK_KEX2_1 | 82 | 84 | PF00082 | 0.443 |
CLV_PCSK_PC1ET2_1 | 82 | 84 | PF00082 | 0.539 |
CLV_PCSK_PC7_1 | 7 | 13 | PF00082 | 0.572 |
CLV_PCSK_SKI1_1 | 85 | 89 | PF00082 | 0.405 |
CLV_PCSK_SKI1_1 | 99 | 103 | PF00082 | 0.428 |
DOC_MAPK_gen_1 | 79 | 89 | PF00069 | 0.443 |
DOC_MAPK_MEF2A_6 | 142 | 150 | PF00069 | 0.423 |
DOC_USP7_MATH_1 | 151 | 155 | PF00917 | 0.410 |
DOC_USP7_MATH_1 | 179 | 183 | PF00917 | 0.378 |
DOC_USP7_MATH_1 | 57 | 61 | PF00917 | 0.605 |
DOC_USP7_UBL2_3 | 138 | 142 | PF12436 | 0.540 |
LIG_14-3-3_CanoR_1 | 189 | 194 | PF00244 | 0.473 |
LIG_14-3-3_CanoR_1 | 83 | 88 | PF00244 | 0.414 |
LIG_FHA_1 | 84 | 90 | PF00498 | 0.409 |
LIG_FHA_2 | 105 | 111 | PF00498 | 0.519 |
LIG_FHA_2 | 4 | 10 | PF00498 | 0.613 |
LIG_FHA_2 | 45 | 51 | PF00498 | 0.681 |
LIG_PTB_Apo_2 | 69 | 76 | PF02174 | 0.432 |
LIG_SH2_STAT3 | 118 | 121 | PF00017 | 0.601 |
LIG_SH2_STAT5 | 118 | 121 | PF00017 | 0.406 |
LIG_SH2_STAT5 | 147 | 150 | PF00017 | 0.484 |
LIG_SUMO_SIM_anti_2 | 130 | 136 | PF11976 | 0.504 |
MOD_CK2_1 | 179 | 185 | PF00069 | 0.435 |
MOD_CK2_1 | 3 | 9 | PF00069 | 0.547 |
MOD_GlcNHglycan | 28 | 31 | PF01048 | 0.417 |
MOD_GSK3_1 | 21 | 28 | PF00069 | 0.591 |
MOD_N-GLC_1 | 179 | 184 | PF02516 | 0.384 |
MOD_N-GLC_1 | 26 | 31 | PF02516 | 0.528 |
MOD_N-GLC_1 | 71 | 76 | PF02516 | 0.429 |
MOD_NEK2_1 | 104 | 109 | PF00069 | 0.438 |
MOD_NEK2_1 | 146 | 151 | PF00069 | 0.426 |
MOD_NEK2_1 | 26 | 31 | PF00069 | 0.515 |
MOD_NEK2_1 | 94 | 99 | PF00069 | 0.501 |
MOD_PKA_1 | 189 | 195 | PF00069 | 0.441 |
MOD_PKA_2 | 189 | 195 | PF00069 | 0.527 |
MOD_PKA_2 | 44 | 50 | PF00069 | 0.705 |
MOD_PKB_1 | 10 | 18 | PF00069 | 0.602 |
MOD_Plk_1 | 26 | 32 | PF00069 | 0.479 |
MOD_Plk_4 | 104 | 110 | PF00069 | 0.433 |
MOD_Plk_4 | 71 | 77 | PF00069 | 0.542 |
MOD_SUMO_rev_2 | 60 | 64 | PF00179 | 0.632 |
TRG_ENDOCYTIC_2 | 147 | 150 | PF00928 | 0.487 |
TRG_ER_diArg_1 | 10 | 12 | PF00400 | 0.539 |
TRG_ER_diArg_1 | 188 | 191 | PF00400 | 0.584 |
Protein | Taxonomy | Sequence identity | Coverage |
---|---|---|---|
A0A3Q8IEM8 | Leishmania donovani | 77% | 100% |
A0A422N4H9 | Trypanosoma rangeli | 44% | 70% |
A4I389 | Leishmania infantum | 77% | 100% |
D0A7R5 | Trypanosoma brucei gambiense (strain MHOM/CI/86/DAL972) | 41% | 67% |
E9AZH7 | Leishmania mexicana (strain MHOM/GT/2001/U1103) | 76% | 100% |
Q4Q8Q4 | Leishmania major | 76% | 100% |
V5BGL1 | Trypanosoma cruzi | 45% | 70% |